Open access peer-reviewed Edited Volume

Recent Advances in Cardiotoxicity

Wenyong Tan

Southern Medical University

An active clinical translational researcher with the main focus on optimizing the cancer treatment strategies and minimizing cancer therapy-associated cardiac toxicities, European Society of Radiotherapy Oncology (ESTRO) Fellow and holder of four registered patents.


Drug-Induced Cardiotoxicity Cytotoxic Agents Molecular Target Drug Immune Checkpoint Inhibitors Heart Failure Cardiac Dysfunction Hypertension Ischemic Heart Disease Recognition Prevention Biomarkers Cardiac Sparing Techniques

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

As the diagnostic and therapeutic modalities have been rapidly improved in the past several decades,most medical intervention techniques and/or drugs, especially for the anti-cancer treatment, might unavoidably result in various cardiotoxicities. Most anti-cancer treatments were found to be associated with various cardiovascular side effects impacting cancer patient’s outcomes, which has been a heavy concern both in the oncology and cardiology community. It has also been reported that cardiovascular causes are responsible for the death of 33% of cancer survivors. Most anti-cancer agents including cytotoxic drugs, molecular target agents and immune checkpoint inhibitors might induce acute or chronic cardiac toxicities and each of them has its own molecular mechanisms to the cardiac damage. Similarly, Radiation therapy, especially radiotherapy to the thoracic tumors, will unavoidably deliver an unnecessary radiation dose to the heart and result in some cardiac toxicities.

Though cardiovascular diseases in cancer patients can precede the diagnosis of cancer or can be related to the malignancy itself or its therapy, the oncologists and cardiologist should collaborate tightly to optimize the anti-cancer strategies and cardiovascular conditions before, during and after the cancer treatment course to best the patient’s outcome. Also, scientists should widely investigate mechanisms of cardiotoxicities to better manage side effects and promote advanced cardiovascular discoveries.

The recognition, prevention, monitoring (biomarkers or imaging), management of cancer treatment heart disease should be critical for the clinical practice and many cardiac sparing strategies have been developed and used in breast cancer, lung cancer, etc, which seem to minimize cancer treatment-related cardiac toxicities. In addition, some painkillers, and medical treatment also lead to a kind of cardiotoxicities, which would be introduced in this book.

Publishing process

Book initiated and editor appointed

Date completed: April 26th 2021

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: May 24th 2021

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: July 23rd 2021

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 11th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 10th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Wenyong Tan

Southern Medical University

Prof. Dr. Wenyong Tan has been a clinical oncologist for more than 20 years, and he is the director of the Department of Oncology, Shenzhen Hospital of Southern Medical University. Dr. Tan He has been devoted to the radiotherapy and anti-cancer drugs therapy cancer diagnosis and treatment, especially focusing on lung cancer, breast cancer as well as head and neck cancer. He is also an active clinically translational researchers and mainly focus on the optimizing the cancer treatment strategies and minimizing the cancer therapy associated cardiac toxicities. Dr. Tan has published more than 50 academic papers in collaboration with co-authors and nine international academic meeting abstracts.

View profile

Book chapters authored 1

Books edited 1

Introducing your Author Service Manager

Ms. Dolores Kuzelj

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in